Upgrade of exsiting Orbitrap Exploris 480

The Novo Nordisk Foundation Center for Protein Research (CPR) is a research center of excellence established at University of Copenhagen in 2007 to promote basic and applied discovery research on human proteins of medical relevance. The primary focus of the work at the CPR is within protein research and the areas of disease mechanisms, disease systems biology and mass spectrometry-based proteomics research in particular.

The purchase is a replacement/upgrade of already existing installations, in a shared facility at the University of Copenhagen. The acquisition is used in research and development, in basic research and applied research into human proteins of medical relevance.

The new HRAM instrument is a novel MS system with unique characteristics tailored to excel in a broad range of proteomics experiments. No other provider offers similar equipment capable of HRAM measurements of comparable high sensitivity, speed, and dynamic range in LC-MS/MS experiment.

As the Orbitrap and the novel HRAM analyzers’ technology is patented, for technical reasons the contract can only be assigned to one specific economic actor.

The need to use high throughput and sensitive label-free Data Independent

As the Orbitrap and the novel HRAM analyzers’ technology is patented, for technical reasons the contract can only be assigned to one specific economic actor.

The need to use high throughput and sensitive label-free Data Independent Acquisition (DIA)-based and labeled multiplexed TMT18-based peptide quantification strategies, which is only possible on the new HRAM instrument.

The Orbitrap HRAM mass spectrometer is the subject of patent applications filed and published in multiple countries.

GB2612574A, GB2605395A, GB2608352A, GB2608365A, US20230118221A1, GB2583758B, GB2608365A, EP3410463B1, GB2575169B, GB2527898B, GB2515407A

No other provider can offer similar equipment as part of a complete LC-MS solution. The desired equipment has novel hardware architecture combining high-selectivity quadrupole mass filter, Orbitrap technology and the novel HRAM technology. In this unique configuration, the Orbitrap provides high dynamic range No other provider can offer similar equipment as part of a complete LC-MS solution. The desired equipment has novel hardware architecture combining high-selectivity quadrupole mass filter, Orbitrap technology and the novel HRAM technology. In this unique configuration, the Orbitrap provides high dynamic range HRAM full MS scans, quadrupole mass filter allows for efficient precursor selection, while the new HRAM analyzer provides fast (up to 200 Hz) and sensitive high dynamic range HRAM MS/MS scans. It has the same user interface and implementation as the existing equipment allowing for the direct method transfer. The client needs to be able to analyze e.g. whole cell proteome samples or enriched phosphopeptide samples with fast and sensitive label-free DIA and/or labeled TMT18-based multiplexed quantitative approaches and therefore needs equipment that is capable of high-resolution accurate mass high dynamic range full MS scans, coupled to the fast, sensitive high dynamic range high-resolution accurate mass HCD MS/MS scans. To achieve sufficiently high MS/MS sensitivity, dynamic range and acquisition rate, the contracting authority needs a new HRAM technology-based mass spectrometer with the possibility of HCD fragmentation. As the Orbitrap and the novel HRAM analyzers’ technology is patented, the contract can therefore only be transferred to one specific economic actor for technical reasons. The equipment provides full integration into existing work routines, as it is a replacement of the existing Orbitrap Exploris systems. A change of supplier will therefore entail technical incompatibility and disproportionately large replacement costs. Such a change will also necessitate changes to integrated software systems, which are very resource-intensive and will therefore put us far behind in terms of competition.